Efficacy and safety of azithromycin eye drops in treatment of bacterial conjunctivitis: a Meta-analysis
10.13699/j.cnki.1001-6821.2019.07.031
- VernacularTitle:阿奇霉素滴眼液治疗细菌性结膜炎的临床疗效和安全性的Meta分析
- Author:
Feng WU
1
;
Xiu-Li ZHAO
;
Yu-Yang DAI
;
Yi-Min CUI
Author Information
1. 北京大学 第一医院 药学部
- Keywords:
azithromycin eye drop;
bacterial conjunctivitis;
Meta-analysis;
randomized controlled trial
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(7):706-708,711
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systemically evaluate the efficacy and safety of azithromycin eye drops in treatment of bacterial conjunctivitis.Methods Databases including PubMed, EmBase, the Cochrane Library, CNKI, VIP and WanFang were searched to identify randomized controlled trials (RCT) of azithromycin eye drops in treatment of bacterial conjunctivitis up to December, 2018. Two researchers independently screened the articles, extracted data and assessed the trials qualities. The Meta-analysis was performed using RevMan 5. 3 software to evaluate the clinical cure, bacteriological resolution, and adverse reaction of two treatment groups. Results A total of 6 RCTs (2874 patients) were eligible. The results of Meta-analysis showed that azithromycin eye drops was non-inferior to tobramycin eye drops in both clinical cure (87. 6％vs. 85. 6％, P> 0. 05) and bacteriological resolution rates (91. 9％ vs.92. 7％, P> 0. 05) , while azithromycin showed obvious superiority to tobramycin in the earlier clinical cure rate (35. 8％ vs. 22. 2％, P < 0. 001) . There was no significant difference in the adverse reaction rate (1. 7％ vs. 2. 3％, P> 0. 05) . Compared with placebo, azithromycinshowed advantages in both clinical cure and bacteriological resolution (P < 0. 05, P < 0. 001) . Conclusion Azithromycin eye drops have favorable efficacy, good safety profile and superior earlier effectiveness in treatment of bacterial conjunctivitis, however further RCTs of higher quality are needed to validate it.
